NASDAQ$TECX

Tectonic Therapeutic Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$23K

Previous: $0.00
EPS (adj)

-$0.44

Previous: -$0.52+15.4%
R&D Expenses

$8.13M

Previous: $15.9M-48.9%
G&A Expenses

$1.98M

Previous: $7.07M-72.0%
Capital Expenditures

-$8K

Previous: $86K-109.3%
Free Cash Flow

-$21.6M

Previous: -$16.5M-30.8%
Net Income

-$21.6M

Previous: -$23M+6.1%
Operating Income

-$22.9M

Previous: -$23M+0.2%
Gross Profit

-$460K

No prior period
Cash & Equivalents

$106M

Previous: $116M-8.7%
Total Assets

$111M

Previous: $129M-14.7%
R&D Expense

$14.8M

No prior period
Stock-Based Comp

$2.22M

Previous: $2.66M-16.4%

Revenue & EPS history

Tectonic · Revenue · Quarterly

$23K

Q3 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-1.4%

Avg return

Earnings day

-1.0%

Avg return

5 days after

+2.9%

Avg return

30 days after

41%

7 / 17 earnings

Positive

+11.1%

Q4 2021

Best reaction

-20.3%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.4%+14.5%+22.6%
Q3 2025+1.5%-0.7%+4.9%
Q1 2025-0.9%+3.5%-13.4%
Q4 2024+1.0%-11.8%+11.0%
Q3 2024-2.0%+6.5%+14.8%
Q1 2024+0.0%-0.8%-7.0%
Q4 2023+0.8%-2.3%-1.6%
Q3 2023-9.9%-13.2%-7.2%
Q2 2023+0.6%-1.9%+4.5%
Q1 2023-4.5%-4.5%+82.1%
Q4 2022-20.3%-14.6%-23.6%
Q3 2022-1.5%+12.1%+19.7%
Q2 2022+5.0%+5.9%-12.9%
Q1 2022-7.3%-1.2%+30.5%
Q4 2021+11.1%+12.5%-20.8%
Q3 2021-1.0%-3.8%-40.7%
Q2 2021+6.5%-17.0%-13.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro